Skip to main content

Sanford Studying Immunotherapy Drug for Esophageal Cancer

A clinical trial at Sanford Health is studying if an immunotherapy drug developed by Merck might be able to treat certain patients with advanced esophageal cancer. The Merck Keynote 181 trial is now open at Sanford.
http://bioplushealth.com/bph/sanford-studying-immunotherapy-drug-for-esophageal-cancer/
 

AUDIENCES

SUBJECTS

Disclaimer: This information is for educational purposes only, It is not to diagnose or treat your disease. If you do use the information contained on this web site without the approval of a health professional, you are prescribing for yourself, which is your constitutional right, but the author(s) and webmaster assume no responsibility

© 2024 Esophageal Cancer Education Foundation- by domino